Compare CCK & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCK | JAZZ |
|---|---|---|
| Founded | 1906 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.4B |
| IPO Year | 2003 | 2007 |
| Metric | CCK | JAZZ |
|---|---|---|
| Price | $100.92 | $182.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $122.67 | ★ $216.92 |
| AVG Volume (30 Days) | 845.2K | ★ 937.7K |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | ★ 79.72 | N/A |
| EPS | ★ 6.38 | N/A |
| Revenue | ★ $11,665,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $5.26 | $6.17 |
| Revenue Next Year | $2.40 | $7.66 |
| P/E Ratio | $15.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $75.98 | $95.49 |
| 52 Week High | $116.62 | $198.00 |
| Indicator | CCK | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 35.12 | 54.60 |
| Support Level | $98.85 | $176.67 |
| Resistance Level | $102.09 | $182.99 |
| Average True Range (ATR) | 2.41 | 4.96 |
| MACD | -1.01 | -0.92 |
| Stochastic Oscillator | 17.93 | 41.56 |
Crown Holdings Inc is a producer of metal packaging. The company manufactures beverage cans, metal food cans, and closures, as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.